<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">mvjr</journal-id><journal-title-group><journal-title xml:lang="en">Medical Herald of the South of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Медицинский вестник Юга России</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-8075</issn><issn pub-type="epub">2618-7876</issn><publisher><publisher-name>The Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2219-8075-2021-12-3-50-54</article-id><article-id custom-type="elpub" pub-id-type="custom">mvjr-1384</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>The role of transcription factor FoxP3 as a predictor of acute and chronic urticaria in children</article-title><trans-title-group xml:lang="ru"><trans-title>Роль транскрипционного фактора FoxP3 как предиктора развития острой и хронической крапивницы у детей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мальцев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maltsev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мальцев Станислав Викторович, к.м.н., доцент, заведующий педиатрическим отделением клиники</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Stanislav V. Maltsev, Сand. Sc. (Med.), associate Professor, head of pediatric Department of clinic</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">steve30@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сизякина</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Sizyakina</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сизякина Людмила Петровна, д.м.н., проф., заведующая кафедрой клинической иммунологии и аллергологии</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Lyudmila P. Sizyakina, Dr. Sc. (Med.), Professor, head of the Department of clinical immunology and Allergology</p><p>Rostov-on-Don</p><p> </p></bio><email xlink:type="simple">msizyakina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебеденко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лебеденко Александр Анатольевич, д.м.н., проф., заведующий кафедрой детских болезней №2</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Alexander A. Lebedenko, Dr. Sc. (Med.), Professor, head of the Department of children’s diseases №2</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">leb.rost@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО Ростовский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2021</year></pub-date><volume>12</volume><issue>3</issue><fpage>50</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Maltsev S.V., Sizyakina L.P., Lebedenko A.A., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Мальцев С.В., Сизякина Л.П., Лебеденко А.А.</copyright-holder><copyright-holder xml:lang="en">Maltsev S.V., Sizyakina L.P., Lebedenko A.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medicalherald.ru/jour/article/view/1384">https://www.medicalherald.ru/jour/article/view/1384</self-uri><abstract><p>Objective: To study the transcription factor FoxP3 in children with acute and chronic spontaneous urticaria as a possible predictor of the severity and chronicity of urticaria.Materials and Methods: A total of 264 children of both sexes aged from 6 to 16 years old with diff erent variants of urticaria course were examined. Clinical methods of the study included the analysis of anamnestic data and an objective examination of the child with the determination of the severity of urticaria. Immunological methods of the study included the identifi cation of T-regulatory lymphocytes with the CD4+CD25+ Foxp3+CD45+immunophenotype.Results: A signifi cant decrease in the level of transcription factor FoxP3 was found in children with severe acute urticaria and chronic urticaria compared to the control group.Conclusion: Th e degree of reduction in the level of FoxP3 signifi cantly aff ected the likelihood of the development of a severe course of acute urticaria and possible chronization of the disease.</p></abstract><trans-abstract xml:lang="ru"><p>Цель: изучить транскрипционный фактор FoxP3 у детей с острой и хронической спонтанной крапивницей, как возможный предиктор тяжести и хронизации крапивницы.Материалы и методы: обследовано 264 ребенка обоих полов, 6 – 16 лет с различными вариантами течения крапивницы. Клинические методы исследования включали анализ анамнестических данных, объективный осмотр ребенка с определением степени тяжести крапивницы. Иммунологические методы исследования включали идентификацию Т-регуляторных лимфоцитов с иммунофенотипом CD4+CD25+ Foxp3+CD45+Результаты: установлено значительное снижение уровня транскрипционного фактора FoxP3 у детей с тяжёлым течением острой крапивницы и при хронической крапивнице по сравнению с контрольной группой.Заключение: степень снижения уровня FoxP3 значительно влияет на вероятность развития тяжелого течения острой крапивницы и возможную хронизацию заболевания.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>крапивница</kwd><kwd>дети</kwd><kwd>иммунная система</kwd><kwd>FoxP3</kwd></kwd-group><kwd-group xml:lang="en"><kwd>urticaria</kwd><kwd>children</kwd><kwd>immune system</kwd><kwd>FoxP3</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Urticaria continues to be an urgent, but not fully studied problem of childhood allergy. The prevalence of acute urticaria (AU) in the child population reaches 6.7% [<xref ref-type="bibr" rid="cit1">1</xref>]. According to modern guidelines, AU is the spontaneous occurrence of blisters and/or angioedema for a time period of less than six weeks. Chronic spontaneous urticaria (CU) is diagnosed when symptoms persist for a period of more than six weeks [<xref ref-type="bibr" rid="cit2">2</xref>].</p><p>Visual signs of urticaria are the same in all patients: a blister, angioedema, while the etiology and pathogenesis of their development are diverse. The algorithm for the diagnosis and treatment of urticaria is described in Russian and foreign consent documents, but most often it does not lead to the identification of the disease cause, which is a consequence of the not always determined clinical and pathogenetic characteristics of various variants of the urticaria course [<xref ref-type="bibr" rid="cit3">3</xref>].</p><p>There is a still not fully understood question concerning the dependence of the development of the urticaria course on the functional activity of the child's immune system [4–8]. The implementation of the immune response occurs through a complex system of intercellular interactions and is carried out due to transcription factors; some mechanisms of these interactions are still unclear. Disorders in the work of immune mechanisms underlie the development of many somatic diseases, including the allergic ones. FoxP genes are an integral part of the Fox family, which includes a group of transcription factors united by the forkhead domain. At the present stage, four representatives of this subfamily have been discovered, while FoxP3 is specific for immune cells and is found in CD4+CD8-CD25+ thymocytes, is an important factor in the differentiation and implementation of the functions of CD4+CD25+T-regulatory cells. The important role of regulatory T-cells in the pathogenesis of bronchial asthma has been established [<xref ref-type="bibr" rid="cit9">9</xref>], but this information is contradictory. The research conducted by Lee et al. (2007) showed the presence of an increased number of FoxP3 cells in children with severe bronchial asthma compared with patients with mild asthma [<xref ref-type="bibr" rid="cit10">10</xref>]. At the same time, according to Vale-Pereira et al., the level of FoxP3 was significantly higher in healthy people than in patients with bronchial asthma [<xref ref-type="bibr" rid="cit11">11</xref>]. In this work, the study of the FoxP3 level in allergic pathology (in particular in urticaria in children) is of serious academic interest.</p><p>Due to the ambiguity of ideas about the role of individual structures of the immune system in the urticaria pathogenesis, including transcription factors, it is of scientific interest to study the FoxP3 level and role in children with different urticaria courses, as well as its participation in the urticaria transformation into a chronic form.</p><p>The purpose of the research was to study the transcription factor FoxP3 in children with AU and CU as a possible predictor of the urticaria severity and chronicity.</p></sec><sec><title>Materials and methods</title><p>In order to achieve this goal, 264 children of both sexes aged from 6 to 16 years with various variants of the course of urticaria were examined. The control group included 30 children of both sexes of the same age of health groups I and II b. The examination of patients was carried out on the first day of the child admission before the beginning of therapy in the hospital. An anamnestic criterion for the inclusion of patients in the study was the presence of urticaria episodes lasting no more than six weeks for AU and more than six weeks for CU.</p><p>The clinical methods of the study included the analysis of anamnestic data, an objective examination of the child with the determination of the urticaria severity according to Zuberbier et al. (calculation of the urticaria activity index during the seven days of the patient's stay in the hospital – UAS7) [<xref ref-type="bibr" rid="cit12">12</xref>]. In order to identify T-regulatory lymphocytes with the CD4+CD25+ Foxp3+CD45+ immunophenotype, peripheral blood was taken from the ulnar vein in the morning on an empty stomach into a test tube with a heparin sodium salt spray. Therefore, 100 µl of whole heparinized blood and 20 µl of monoclonal antibodies to CD4+ stained with fluorochrome PE (R-phycoerythrin, phycoerythrin), CD25+ stained with PC5 (Phycoerythrin Cyanine 5.1), CD45+ stained with ECD (Phycoerythrin Texas Red) of Beckman Coulter, USA manufacturer were added in a cytometric test tube. The contents of the cytometric tube were mixed on a vortex and incubated for 20 minutes at a temperature of 18–20° C in a dark place. This stage provided staining of surface markers of T-lymphocytes. Next, T-lymphocytes were treated with Intra Prep Permeabilization Reagent (Immunotech) in accordance with the manufacturer's instructions, then intracellular Foxp3 staining (FITC) was performed with appropriate monoclonal antibodies (manufacturer eBioscience). The expression of the studied T-lymphocyte antigens as a result of multicolored staining was analyzed using a Cytomics FC 500 flow cytometer (Beckman Coulter). The results were presented as a percentage of positive cells. Cell populations were identified using the CXP software (Beckman Coulter, USA), based on the obtained parameters, the lymphoid region was isolated on a dot plot for the subsequent analysis of cells subpopulations with mandatory control of the lymphoid gate allocation purity by CD45 staining. At least 25 thousand events were counted in each studied sample. All the laboratory tests were carried out once. The informed consent for conducting a clinical trial and taking blood from a vein was obtained from parents of children under 15 years of age and from adolescents of 15 years and older.</p><p>The data was checked for the normality of the distribution by means of the Shapiro-Wilk test. As descriptive statistics for quantitative indices, the average ± mean square deviations, median and quartiles, minimum and maximum values in the sample were calculated. The comparison of medians in the groups was carried out according to the Kruskal-Wallis test (pairwise a posteriori comparisons were made according to the Nemenyi method). The differences were recognized as statistically significant at the level of p &lt; 0.05. The calculations were performed in R (version 3.2, R Foundation for Statistical Computing, Vienna, Austria). The analysis of the bond strength was performed using correlation coefficients. The relationship between qualitative and quantitative (or ordinal) indices was analyzed using the Goodman gamma correlation. Also, correlations were recognized as statistically significant at the level of p &lt; 0.05.</p></sec><sec><title>Results</title><p>An analysis of anamnestic data, clinical manifestations (urticaria, itching), UAS7 values found that a mild course of AU (UAS7 7 – 15 points) was observed in 36 children, moderate (UAS7 16–27 points) — in 139 children, severe AU (UAS7 28 – 42 points) — in 61 children, and CU of varying activity degrees was recorded in 28 children.</p><p>While determining the levels of the transcription factor FoxP3 in children with various urticaria variants, a significant decrease in its level was recorded in children with severe AU and CU compared to the control group of healthy children (1.23 ± 0.3%, median 1.37% in severe AU, 0.89 ± 0.084%, median 0.88% in CU; 4.08 ± 00.41%, median 4.15% in the control group).</p><p>The FoxP3 index in all the studied and in the control groups did not show a statistically significant difference from the normal distribution law (the Shapiro-Wilk test). Thus, one can assume the normality of the distribution according to the indicator of the functioning of the immune system “FoxP3” (Table 1).</p><table-wrap id="table-1"><caption><p>Table 1</p><p>Descriptive statistics of the FOXP3 index in groups of children with acute and chronic urticaria</p></caption><table><tbody><tr><td>CD4+CD25+ Foxp3+ CD45+ with a light current of AU, %</td><td>2.81±0.32</td><td>2.75</td><td>[ 2.59; 2.87]</td><td>2.48</td><td>3.36</td><td>0.003</td></tr><tr><td>CD4+CD25+ Foxp3+ CD45+ with a moderate current of AU, %</td><td>1.89±0.23</td><td>1.97</td><td>[ 1.77; 2.08]</td><td>1.54</td><td>2.21</td><td>0.002</td></tr><tr><td>CD4+CD25+ Foxp3+ CD45+ with a severe course of AU, %</td><td>1.23±0.3</td><td>1.37</td><td>[ 1.02; 1.47]</td><td>0.73</td><td>1.73</td><td>0.08</td></tr><tr><td>CD4+CD25+ Foxp3+ CD45+ in CU, %</td><td>0.89±0.084</td><td>0.88</td><td>[ 0.85; 0.93]</td><td>0.74</td><td>1.04</td><td>0.24</td></tr><tr><td>CD4+CD25+ Foxp3+ CD45+ in the control group, %</td><td>4.08±0.41</td><td>4.15</td><td>[ 3.87; 4.35]</td><td>3.25</td><td>4.83</td><td>1</td></tr></tbody></table></table-wrap><p>When comparing the levels of the FoxP3 index in children in pairs using the Nemenyi method, statistically significant differences were found in different variants of the urticaria course from children of the control group (Table 2, Fig. 1).</p><table-wrap id="table-2"><caption><p>Table 2</p><p>Levels of statistical significance for comparing the medians of the CD4+CD25+ Foxp3+ CD45 index + in pairs in groups (CONTROL, Mild AU, Moderate AU, Severe AU, CU)</p></caption><table><tbody><tr><td>CD4+CD25+ Foxp3+ CD45+</td><td>0.6</td><td>0.001</td><td>&lt;0.0001</td><td>&lt;0.0001</td><td>0.2</td></tr></tbody><tbody><tr><td>CD4+CD25+ Foxp3+ CD45+</td><td>&lt;0.0001</td><td>&lt;0.0001</td><td>0.004</td><td>&lt;0.0001</td><td>0.2</td></tr></tbody></table></table-wrap><fig id="fig-1"><caption><p>Figure 1. Span chart for “FoxP3, %”.</p></caption><graphic xlink:href="mvjr-12-3-g001.png"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/mvjr/2021/3/QFfXpjURwozg48piybC8qzyPQvIXazMH8cwOgn0i.png</uri></graphic></fig><p>Statistically significant differences in the FoxP3 indices were found in the following groups of examined children: “Control/Moderate AU”, “Control/Severe AU”, “Control/CU”, “Mild AU/Severe AU”, “Mild AU/CU”, “Moderate AU/Severe AU”, “Moderate AU/CU”.</p><p>Further, in the course of the work, the relationship between the level of the FoxP3 index and the probability of developing a severe urticaria course was evaluated (Table 2).</p><table-wrap id="table-3"><caption><p>Table 3</p><p>Statistically significant correlation between the studied indices</p></caption><table><tbody><tr><td>CD4+CD25+ Foxp3+ CD45+</td><td>Severity of urticaria</td><td>0.97</td><td>&lt;0.0001</td></tr></tbody></table></table-wrap><p>As can be seen from Table 3, a significant strong relationship was found between the variables “CD4+CD25+ Foxp3+ CD45+” and “Severity of urticaria”.</p></sec><sec><title>Discussion</title><p>Thus, this work shows that all the patients with AU and CU are characterized by a significant decrease in the proportion of CD4+CD25+ Foxp3+ CD45+ in peripheral blood, which probably causes a decrease in their functional activity. At the same time, there is a statistically significant relationship between the level of the Foxp3 index and the urticaria severity.</p></sec><sec><title>Conclusion</title></sec></body><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Горячкина Л.А., Ненашева Н.М., Борзова Е.Ю. Крапивница // Лечащий врач. – 2003. – №9. – С. 43-45.</mixed-citation><mixed-citation xml:lang="en">Goryachkina LA, Nenasheva NM, Borzova EYU. Urticaria. Attending physician. 2003;(9):43-45. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральные клинические рекомендации по оказанию медицинской помощи детям с крапивницей. – М.: Союз педиатров России, 2016.</mixed-citation><mixed-citation xml:lang="en">Federal clinical guidelines for the care of children with urticaria. Union of pediatricians of Russia; 2015. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Яловега Г.Э., Лебеденко А.А., Калмыкова Т.С., Аверкина Л.А., Посевина А.Н., и др. Особенности микроэлементного статуса у детей с острой крапивницей // Педиатрическая фармакология. – 2016. – №2. – С. 101-104. DOI: 10.15690/pf.v13i2.1550</mixed-citation><mixed-citation xml:lang="en">Yalovega G.E., Lebedenko A.A., Mal’tsev S.V., Kalmykova T.S., Averkina L.A., et al. Features of the microelement status in children with acute urticaria. Pediatric pharmacology. 2016;13(2):101-104. (In Russ.). DOI: 10.15690/pf.v13i2.1550</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мальцев С.В., Сизякина Л.П., Лебеденко А.А. Особенности адаптивного и врожденного иммунитета у детей с различными вариантами течения острой крапивницы // Цитокины и воспаление. – 2014. – №3. – С. 117-118. eLIBRARY ID: 22840551</mixed-citation><mixed-citation xml:lang="en">Malcev S.V., Sizyakina L.P., Lebedenko A.A. Features of adaptive and innate immunity in children with diff erent variants of acute urticarial. Cytokines and infl ammation. 2014;(3): 117-118. (In Russ). eLIBRARY ID: 22840551</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Сизякина Л.П., Андреева И.И. Справочник по клинической иммунологии. – Ростов-на-Дону, 2005.</mixed-citation><mixed-citation xml:lang="en">Sizyakina LP, Andreeva II. Handbook of clinical immunology. Rostov-on-Don; 2005. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сизякина Л.П., Лебеденко А.А., Мальцев С.В., Посевина А.Н., Аверкина Л.А. Крапивница у детей: современный взгляд на проблему // Медицинский вестник Юга России. – 2015. – №4. – С. 5-13. DOI: 10.21886/2219-8075-2015-4-5-13</mixed-citation><mixed-citation xml:lang="en">Sizyakina L.P., Lebedenko A.A., Malcev S.V., Posevina A.N., Averkina L.A. Murticaria in children: a modern view on the problem. Medical Herald of the South of Russia. 2015;(4):5-13. (In Russ.) DOI: 10.21886/2219-8075-2015-4-5-13</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y.R., Liu T.H., Wu T.K., Chang Y.J., Chou C.C., Wu H.P. Predictive factors of the duration of a fi rst-attack acute urticaria in children // Am J Emerg Med. – 2011. – Vol. 29. – P.883-889. DOI: 10.1016/j.ajem.2010.04.004.</mixed-citation><mixed-citation xml:lang="en">Lin YR, Liu TH, Wu TK, Chang YJ, Chou CC, Wu HP. Predictive factors of the duration of a fi rst-attack acute urticaria in children. Am J Emerg Med. 2011;29(8):883-9. DOI: 10.1016/j.ajem.2010.04.004</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mathur A.N., Mathes E.F. Urticaria mimickers in children // Dermatol Th er. – 2013. – Vol. 26. – P. 467-475. DOI: 10.1111/dth.12103.</mixed-citation><mixed-citation xml:lang="en">Mathur AN, Mathes EF. Urticaria mimickers in children. Dermatol Ther. 2013;26(6):467-75. DOI: 10.1111/dth.12103.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Минеев В.Н., Сорокина Л.Н., Еремеева А.В., Нема М.А., Беденко А.С. Патогенетическая роль кооперативных взаимодействий транскрипционных факторов FoxP3, GATA-3, PAX-5 при бронхиальной астме // Медицинская иммунология. – 2013. – №4. – С. 303-312. eLIBRARY ID: 20143594</mixed-citation><mixed-citation xml:lang="en">Mineev V.N., Sorokina L.N., Eremeeva A.V., Nema M.A., Bedenko A.S. Pathogenetic role of cooperative interactions of transcription factors FoxP3, GATA-3, PAX-5 in bronchial asthma. Medical immunology. 2013;(4):303-312. (In Russ). eLIBRARY ID: 20143594</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.H., Yu H.H., Wang L.C., Lin Y.-T., Chiang B.L. The levels of CD4+CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma // Clin. Exp. Immunol. – 2007. – Vol. 148, iss. 1. – Р. 53-63. DOI: 10.1111/j.1365-2249.2007.03329.x</mixed-citation><mixed-citation xml:lang="en">Lee JH, Yu HH, Wang LC, Yang YH, Lin YT, Chiang BL. The levels of CD4+CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma. Clin Exp Immunol. 2007;148(1):53-63. DOI: 10.1111/j.1365-2249.2007.03329.x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Vale-Pereira S., Todo-Bom A., Geraldes L., Schmidt-Weber C., Akdis C.A., Mota-Pinto A. FoxP3, GATA-3 and T-bet expression in elderly asthma. // Clin. Exp. Allergy. – 2011. – Vol. 41, iss. 4. – Р. 490-496. DOI: 10.1111/j.1365-2222.2010.03640.x</mixed-citation><mixed-citation xml:lang="en">Vale-Pereira S, Todo-Bom A, Geraldes L, Schmidt-Weber C, Akdis CA, Mota-Pinto A. FoxP3, GATA-3 and T-bet expression in elderly asthma. Clin Exp Allergy. 2011;41(4):490-6. DOI: 10.1111/j.1365-2222.2010.03640.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zuberbier T., Asero R., Bindslev-Jensen C., Walter Canonica G., Church M.K., et al. EAACI/GA(2)LEN/EDF/WAO guideline: defi nition, classifi cation and diagnosis of urticarial // Allergy. – 2009. – Vol. 64. №10. – P. 1417-1426. DOI: 10.1111/j.1398-9995.2009.02179.x</mixed-citation><mixed-citation xml:lang="en">Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, et al. EAACI/GA(2)LEN/EDF/WAO guideline: defi nition, classifi cation and diagnosis of urticaria. Allergy. 2009;64(10):1417-26. DOI: 10.1111/j.1398-9995.2009.02179.x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
